Acute Myocardial Infarction Study in Northeastern China

Acute Myocardial Infarction Clinical Trial

Official title:

the Acute Myocardial Infarction Study in Northeastern China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04451967
• Other study ID #: SecondJilinU-AMINoC
• Status: Recruiting
• Start date: September 9, 2019
• Est. completion date: September 9, 2022

Study information

• Verified date: June 2020
• Source: Second Hospital of Jilin University
• Contact: Tianyi Li, Ph.D
• Phone: +8615843024731
• Email: litianyi[@]jlu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a real-world prospective cohort study aiming to generate knowledge about the characteristics, treatments, and outcomes of hospitalized AMI patients in Jilin Province. The study includes hospitalizations diagnosed of AMI, including ST segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarction (NSTEMI).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3159
• Est. completion date: September 9, 2022
• Est. primary completion date: September 9, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patients admitted within 7 days of acute myocardial ischemic symptoms with a primary clinical diagnosis of AMI, meet Fourth Universal Definition for Myocardial Infarction (2018)

Exclusion Criteria:

• Types 4a and type 5 AMI

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Infarction
• Myocardial Infarction

Intervention

Procedure:
• thrombolysis
transfer after thrombolysis for STEMI patients within 6h since onset

Locations

Country	Name	City	State
China	The second hospital of Jilin university	Changchun	Jilin

Sponsors (20)

Lead Sponsor

Collaborator

Second Hospital of Jilin University

Baicheng Central Hospital, Baishan Central Hospital, Beihua University, Changchun Center Hospital, Changling People's Hospital, Dongliao People's Hospital, Dunhua City Hospital in Jilin Province, Jilin Hospital of Integrated Traditional Chinese and Western Medicine, Jingyu People's Hospital, Liaoyuan City Central Hospital, Meihekou Central Hospital, Nongan People's Hospital, Panshi City Hospital, Siping Central Hospital, Songyuan Central Hospital, The First People's Hospital of Manchu Autonomous County, Tonghua Central Hospital, Tongyu First Hospital, Yanbian University Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all-cause death	all-cause death	2 years post discharge
Secondary	major adverse cardiac events (MACE)	recurrent angina, non-fatal myocardial infarction, cardiac failure, malignant arrhythmia, and death from cardiovascular causes	2 years post discharge